Alfredo Sanchez

Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain.

Journal: The Lancet regional health. Europe

Published: April 10, 2025

Certification system for multidisciplinary thoracic tumour boards.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: August 05, 2024

Difficulties on the access to innovative targeted therapies for lung cancer in Spain.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 25, 2023

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement.

Journal: Journal of clinical medicine

Published: July 14, 2023

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.

Journal: BMC cancer

Published: January 19, 2022

Dendrimers as Soft Nanomaterials for Electrochemical Immunosensors.

Journal: Nanomaterials (Basel, Switzerland)

Published: October 28, 2019

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients.

Journal: Oncology and therapy

Published: May 31, 2019

Correction to: Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 11, 2018

Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: August 30, 2017

Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain.

Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain.

Certification system for multidisciplinary thoracic tumour boards.

Certification system for multidisciplinary thoracic tumour boards.

Difficulties on the access to innovative targeted therapies for lung cancer in Spain.

Difficulties on the access to innovative targeted therapies for lung cancer in Spain.

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement.

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement.

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.

Dendrimers as Soft Nanomaterials for Electrochemical Immunosensors.

Dendrimers as Soft Nanomaterials for Electrochemical Immunosensors.

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients.

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients.

Correction to: Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.

Correction to: Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.

Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.

Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.

Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature.

Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature.

Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study.

Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study.

Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma.

Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma.